Patients were randomized to receive nintedanib ( 250 mg twice daily ) , afatinib ( 40 mg once daily [ q.d. ] ) , or alternating sequential 7-day nintedanib ( 250 mg twice daily ) and afatinib ( 70 mg q.d. [ Combi70 ] ) , which was reduced to 40 mg q.d. ( Combi40 ) due to adverse events .